GlassScriptPhysician profile
Alka S Kale
NPI 1801894969
$2,586.45
in general payments reported to CMS, 2019-2025
29 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $169 · 2021: $483 · 2022: $447 · 2023: $365 · 2024: $547 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.42 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.14 | 2020-2024 | |
| Astellas Pharma US INC | $323.62 | 2022-2024 | Veozah |
| Organon LLC | $220.45 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $208.05 | 2019-2025 | Paragard T 380a |
| Exeltis, USA INC. | $170.62 | 2019-2024 | Slynd |
| Hologic Sales and Service, LLC | $165.23 | 2021-2024 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Genzyme Corporation | $131.10 | 2024 | |
| Phathom Pharmaceuticals, INC. | $110.10 | 2025 | Voquezna |
| Aspira Women'S Health INC | $94.29 | 2021-2024 | Ova1 |
| Lupin INC. | $90.39 | 2019-2020 | |
| Roche Diagnostics Corporation | $87.21 | 2019 | |
| Therapeuticsmd, INC. | $66.57 | 2019-2022 | |
| Agile Therapeutics, INC. | $65.07 | 2021-2024 | Twirla |
| Pfizer INC. | $50.37 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $48.33 | 2019-2025 | Exparel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.79 | 2019-2021 | |
| Alydia Health | $35.62 | 2021 | |
| Amgen INC. | $33.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.77 | 2019 | |
| Gynesonics, INC. | $31.49 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Becton, Dickinson and Company | $27.31 | 2024 | Bd Onclarity |
| Myovant Sciences INC. | $26.01 | 2021 | |
| Biogen, INC. | $19.92 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $16.35 | 2019 | |
| Sumitomo Pharma America, INC. | $16.23 | 2024 | Myfembree |
| Mayne Pharma Commercial LLC | $15.26 | 2022 | |
| Duchesnay USA Incorporated | $12.97 | 2019 | |
| Allergan, INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Kale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.